For COVID-19 Convalescent Plasma Program Requirements Click Here!
News & Views
Newsletters
Donate
Contact
Search
Close
News & Views
Newsletters
Donate
Contact
Search
Close
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Menu
About
About Us
Mission, Vision, Core Values
Centers of Excellence
Research Operations
Office of Human Research Protection Program
Office of Clinical Research Coordination
Office of Grants & Contract Management
DHR Research Academy
Research Partnerships & Affiliations
Partnerships & Affiliations
Partner With Us
Sponsors
Core Facilities
For Research Patients
General Information
Clinical Trials
Para Pacientes
Información General
Ensayos Clínicos
For Investigators
For Industry Sponsors
Knowledge Center
Become A Research Patient
Donate
5323 S. McColl Rd., Edinburg, TX 78539
dhrresearch@dhr-rgv.com
(956) 362-2390
Trial Category: Neonatology
Results
D5290C00004 – A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
View Details →
A MULTI-CENTER PROSPECTIVE ANALYSIS OF NEWBORN DIRECT/CONJUGATED BILIRUBIN SCREENING FOR BILIARY ATRESIA
View Details →
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
View Details →
AL31A-Growth and Tolerance of Young Infants Fed Milk-Based Infant Formula with Oligosaccharides.
View Details →
AL35- Evaluation of Preterm Infants Fed Post-Discharge Preterm Infant Formula with Added Human Milk Oligosaccharide 2’-Fucosyllactose
View Details →
